ES2544640T3 - Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes - Google Patents

Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes

Info

Publication number
ES2544640T3
ES2544640T3 ES13002792.3T ES13002792T ES2544640T3 ES 2544640 T3 ES2544640 T3 ES 2544640T3 ES 13002792 T ES13002792 T ES 13002792T ES 2544640 T3 ES2544640 T3 ES 2544640T3
Authority
ES
Spain
Prior art keywords
cooh
eleven
tat
treatment
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13002792.3T
Other languages
English (en)
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen Inflammation Ltd
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Application granted granted Critical
Publication of ES2544640T3 publication Critical patent/ES2544640T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Péptido inhibidor de JNK consistente en una secuencia de aminoácidos de acuerdo con la SEC ID NO: 2 o péptido quimérico consistente en un primer dominio y un segundo dominio unidos mediante un enlace covalente, comprendiendo el primer dominio una secuencia de tráfico y consistiendo el segundo dominio en una secuencia inhibidora de JNK de acuerdo con la SEC ID NO: 2, para su uso en un método de tratamiento de un trastorno autoinmune cardiovasculares seleccionadas de entre Lupus, Lupus eritematoso y síndrome de Sjögren.

Description

imagen1
imagen2
imagen3
imagen4
E13002792
04-08-2015
Tabla 1
NOMBRE PEPTIDO/ SEQ.
SEC ID NO AA SECUENCIA
L-IB1(s)
1 19 RPKRPTTLNLFPQVPRSQD (NH2-RPKRPTTLNLFPQVPRSQD-COOH)
D-IB1(s)
2 19 DQSRPVQPFLNLTTPRKPR (NH2-DQSRPVQPFLNLTTPRKPR-COOH)
L-IB(genérico)(s)
3 19 NH2-Xn b-Xn a-RPTTLXLXXXXXXXQD-Xn b-COOH
D-IB(genérico) (s)
4 19 NH2-Xn b-DQXXXXXXXLXLTTPR-Xn a-Xn b-COOH
L-TAT
5 10 GRKKRRQRRR (NH2-GRKKRRQRRR-COOH)
D-TAT
6 10 RRRQRRKKRG (NH2-RRRQRRKKRG-COOH)
L-genérico-TAT (s)
7 11 NH2-Xn b-RKKRRQRRR-Xn b-COOH
D-genérico-TAT (s)
8 11 NH2-Xn b-RRRQRRKKR-Xn b-COOH
L-TAT-IB1(s)
9 31 GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD (NH2-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB (genérico) (s)
10 29 NH2-Xn b-RKKRRQRRR-Xn b-Xn a-RPLXLXXXXXXXQD-Xn b-COOH
D-TAT-IB1(s)
11 31 DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG (NH2-DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-COOH)
D-TAT-IB (genérico) (s)
12 29 NH2-Xn b-DQXXXXXXXLXLTTPR-Xn a-Xn b-RRRQRRKKR-Xn b-COOH
IB1-largo
13 29 PGTGCGDTYRPKRPTTLNLFPQVPRSQDT (NH2-PGTGCGDTYRPKRPTTLNLFPQVPRSQDT -COOH)
IB2-largo
14 27 IPSPSVEEPHKHRPTTLRLTTLGAQDS (NH2-IPSPSVEEPHKHRPTTLRLTTLGAQDS -COOH)
c-Jun
15 29 GAYGYSNPKILKQSMTLNLADPVGNLKPH (NH2-GAYGYSNPKILKQSMTLNLADPVGNLKPH -COOH)
ATF2
16 29 TNEDHLAVHKHKHEMTLKFGPARNDSVIV (NH2-TNEDHLAVHKHKHEMTLKFGPARNDSVIV -COOH)
L-IB1
17 23 DTYRPKRPTTLNLFPQVPRSQDT (NH2-DTYRPKRPTTLNLFPQVPRSQDT -COOH)
D-IB1
18 23 TDQSRPVQPFLNLTTPRKPRYTD (NH2-TDQSRPVQPFLNLTTPRKPRYTD -COOH)
L-IB (genérico)
19 19 XRPTTLXLXXXXXXXQDS/TX (NH2-XRPTTLXLXXXXXXXQDS/TX -COOH)
D-IB (genérico)
20 19 XS/TDQXXXXXXXLXLTTPRX (NH2-XS/TDQXXXXXXXLXLTTPRX -COOH)
L-genérico-TAT
21 17 XXXXRKKRRQRRRXXXX (NH2-XXXXRKKRRQRRRXXXX -COOH)
D-genérico-TAT
22 17 XXXXRRRQRRKKRXXXX (NH2-XXXXRRRQRRKKRXXXX -COOH)
L-TAT-IB1
23 35 GRKKRRQRRRPPDTYRPKRPTTLNLFPQVPRSQDT (NH2-GRKKRRQRRRPPDTYRPKRPTTLNLFPQVPRSQDT -COOH)
L-TAT-IB (genérico)
24 42 XXXXXXRKKRRQRRRXXXXXXXXRPTTLXLXXXXXXXQDS/TX (NH2-XXXXXXXRKKRRQRRRXXXXXXXXRPTTLXLXXXXXXXQDS/TX -COOH)
D-TAT-IB1
25 35 TDQSRPVQPFLNLTTPRKPRYTDPPRRRQRRKKRG (NH2-TDQSRPVQPFLNLTTPRKPRYTDPPRRRQRRKKRG -COOH)
D-TAT-IB (genérico)
26 42 XT/SDQXXXXXXXLXLTTPRXXXXXXXXRRRQRRKKRXXXXXXX(NH2-XT/SDQXXXXXXXLXLTTPRXXXXXXXXRRRQRRKKRXXXXXXX -COOH)
L-TAT-IB1(s1)
27 30 RKKRRQRRRPPRPKRPTTLNLFPQVPRSQD (NH2-RKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB1(s2)
28 30 GRKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD (NH2-GRKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD-COOH)
L-TAT-IB1(s3)
29 29 RKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD (NH2-RKKRRQRRRXn cRPKRPTTLNLFPQVPRSQD-COOH)
D-TAT-IB1(s1)
30 30 DQSRPVQPFLNLTTPRKPRPPRRRQRRKKR (NH2-DQSRPVQPFLNLTTPRKPRPPRRRQRRKKR-COOH)
D-TAT-IB1(s2)
31 30 DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKRG (NH2-DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKRG-COOH)
D-TAT-IB1(s3)
32 29 DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKR (NH2-DQSRPVQPFLNLTTPRKPRXn cRRRQRRKKR-COOH)
L-IB1(s1)
33 13 TLNLFPQVPRSQD(NH2-TLNLFPQVPRSQD-COOH)
E13002792
04-08-2015
L-IB1(s2)
34 13 TTLNLFPQVPRSQ(NH2-TTLNLFPQVPRSQ-COOH)
L-IB1(s3)
35 13 PTTLNLFPQVPRS(NH2-PTTLNLFPQVPRS-COOH)
L-IB1(s4)
36 13 RPTTLNLFPQVPR(NH2-RPTTLNLFPQVPR-COOH)
L-IB1(s5)
37 13 KRPTTLNLFPQVP(NH2-KRPTTLNLFPQVP-COOH)
L-IB1(s6)
38 13 PKRPTTLNLFPQV(NH2-PKRPTTLNLFPQV-COOH)
L-IB1(s7)
39 13 RPKRPTTLNLFPQ(NH2-RPKRPTTLNLFPQ-COOH)
L-IB1(s8)
40 12 LNLFPQVPRSQD(NH2-LNLFPQVPRSQD-COOH)
L-IB1(s9)
41 12 TLNLFPQVPRSQ(NH2-TLNLFPQVPRSQ-COOH)
L-IB1(s10)
42 12 TTLNLFPQVPRS(NH2-TTLNLFPQVPRS-COOH)
L-IB1(s11)
43 12 PTTLNLFPQVPR(NH2-PTTLNLFPQVPR-COOH)
L-IB1(s12)
44 12 RPTTLNLFPQVP(NH2-RPTTLNLFPQVP-COOH)
L-IB1(s13)
45 12 KRPTTLNLFPQV(NH2-KRPTTLNLFPQV-COOH)
L-IB1(s14)
46 12 PKRPTTLNLFPQ(NH2-PKRPTTLNLFPQ-COOH)
L-IB1(s15)
47 12 RPKRPTTLNLFP(NH2-RPKRPTTLNLFP-COOH)
L-IB1(s16)
48 11 NLFPQVPRSQD(NH2-NLFPQVPRSQD-COOH)
L-IB1(s17)
49 11 LNLFPQVPRSQ(NH2-LNLFPQVPRSQ-COOH)
L-IB1(s18)
50 11 TLNLFPQVPRS(NH2-TLNLFPQVPRS-COOH)
L-IB1(s19)
51 11 TTLNLFPQVPR(NH2-TTLNLFPQVPR-COOH)
L-IB1(s20)
52 11 PTTLNLFPQVP(NH2-PTTLNLFPQVP-COOH)
L-IB1(s21)
53 11 RPTTLNLFPQV(NH2-RPTTLNLFPQV-COOH)
L-IB1(s22)
54 11 KRPTTLNLFPQ(NH2-KRPTTLNLFPQ-COOH)
L-IB1(s23)
55 11 PKRPTTLNLFP(NH2-PKRPTTLNLFP-COOH)
L-IB1(s24)
56 11 RPKRPTTLNLF(NH2-RPKRPTTLNLF-COOH)
L-IB1(s25)
57 10 LFPQVPRSQD(NH2-LFPQVPRSQD-COOH)
L-IB1(s26)
58 10 NLFPQVPRSQ(NH2-NLFPQVPRSQ-COOH)
L-IB1(s27)
59 10 LNLFPQVPRS(NH2-LNLFPQVPRS-COOH)
L-IB1(s28)
60 10 TLNLFPQVPR(NH2-TLNLFPQVPR-COOH)
L-IB1(s29)
61 10 TTLNLFPQVP(NH2-TTLNLFPQVP-COOH)
L-IB1(s30)
62 10 PTTLNLFPQV(NH2-PTTLNLFPQV-COOH)
L-IB1(s31)
63 10 RPTTLNLFPQ(NH2-RPTTLNLFPQ-COOH)
L-IB1(s32)
64 10 KRPTTLNLFP(NH2-KRPTTLNLFP-COOH)
L-IB1(s33)
65 10 PKRPTTLNLF(NH2-PKRPTTLNLF-COOH)
L-IB1(s34)
66 10 RPKRPTTLNL(NH2-RPKRPTTLNL-COOH)
D-IB1(s1)
67 13 QPFLNLTTPRKPR(NH2-QPFLNLTTPRKPR-COOH)
D-IB1(s2)
68 13 VQPFLNLTTPRKP(NH2-VQPFLNLTTPRKP-COOH)
D-IB1(s3)
69 13 PVQPFLNLTTPRK(NH2-PVQPFLNLTTPRK-COOH)
D-IB1(s4)
70 13 RPVQPFLNLTTPR(NH2-RPVQPFLNLTTPR-COOH)
D-IB1(s5)
71 13 SRPVQPFLNLTTP(NH2-SRPVQPFLNLTTP-COOH)
D-IB1(s6)
72 13 QSRPVQPFLNLTT(NH2-QSRPVQPFLNLTT-COOH)
D-IB1(s7)
73 13 DQSRPVQPFLNLT(NH2-DQSRPVQPFLNLT-COOH)
D-IB1(s8)
74 12 PFLNLTTPRKPR(NH2-PFLNLTTPRKPR-COOH)
D-IB1(s9)
75 12 QPFLNLTTPRKP(NH2-QPFLNLTTPRKP-COOH)
D-IB1(s10)
76 12 VQPFLNLTTPRK(NH2-VQPFLNLTTPRK-COOH)
D-IB1(s11)
77 12 PVQPFLNLTTPR(NH2-PVQPFLNLTTPR-COOH)
D-IB1(s12)
78 12 RPVQPFLNLTTP(NH2-RPVQPFLNLTTP-COOH)
D-IB1(s13)
79 12 SRPVQPFLNLTT(NH2-SRPVQPFLNLTT-COOH)
D-IB1(s14)
80 12 QSRPVQPFLNLT(NH2-QSRPVQPFLNLT-COOH)
D-IB1(s15)
81 12 DQSRPVQPFLNL(NH2-DQSRPVQPFLNL-COOH)
D-IB1(s16)
82 11 FLNLTTPRKPR(NH2-FLNLTTPRKPR-COOH)
D-IB1(s17)
83 11 PFLNLTTPRKP(NH2-PFLNLTTPRKP-COOH)
D-IB1(s18)
84 11 QPFLNLTTPRK(NH2-QPFLNLTTPRK-COOH)
D-IB1(s19)
85 11 VQPFLNLTTPR(NH2-VQPFLNLTTPR-COOH)
D-IB1(s20)
86 11 PVQPFLNLTTP(NH2-PVQPFLNLTTP-COOH)
D-IB1(s21)
87 11 RPVQPFLNLTT(NH2-RPVQPFLNLTT-COOH)
D-IB1(s22)
88 11 SRPVQPFLNLT(NH2-SRPVQPFLNLT-COOH)
D-IB1(s23)
89 11 QSRPVQPFLNL(NH2-QSRPVQPFLNL-COOH)
D-IB1(s24)
90 11 DQSRPVQPFLN(NH2-DQSRPVQPFLN-COOH)
D-IB1(s25)
91 10 DQSRPVQPFL(NH2-DQSRPVQPFL-COOH)
D-IB1(s26)
92 10 QSRPVQPFLN(NH2-QSRPVQPFLN-COOH)
D-IB1(s27)
93 10 SRPVQPFLNL(NH2-SRPVQPFLNL-COOH)
D-IB1(s28)
94 10 RPVQPFLNLT(NH2-RPVQPFLNLT-COOH)
D-IB1(s29)
95 10 PVQPFLNLTT(NH2-PVQPFLNLTT-COOH)
D-IB1(s30)
96 10 VQPFLNLTTP(NH2-VQPFLNLTTP-COOH)
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
ES13002792.3T 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes Active ES2544640T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/EP2008/004341 2008-05-30
PCT/EP2008/004341 WO2009143865A1 (en) 2008-05-30 2008-05-30 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Publications (1)

Publication Number Publication Date
ES2544640T3 true ES2544640T3 (es) 2015-09-02

Family

ID=40347935

Family Applications (5)

Application Number Title Priority Date Filing Date
ES13002793.1T Active ES2531963T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cancerosas
ES13002792.3T Active ES2544640T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes
ES09753692T Active ES2400988T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades
ES12000665T Active ES2443347T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cardiovasculares
ES12000663.0T Active ES2481915T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales jnk para el tratamiento de diversas enfermedades

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13002793.1T Active ES2531963T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cancerosas

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES09753692T Active ES2400988T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades
ES12000665T Active ES2443347T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de enfermedades cardiovasculares
ES12000663.0T Active ES2481915T3 (es) 2008-05-30 2009-06-02 Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales jnk para el tratamiento de diversas enfermedades

Country Status (17)

Country Link
US (2) US9006185B2 (es)
EP (6) EP2650008B1 (es)
JP (3) JP5485265B2 (es)
CN (2) CN102112149A (es)
AR (1) AR070864A1 (es)
AU (1) AU2009253346B2 (es)
CA (1) CA2725545A1 (es)
CY (4) CY1114725T1 (es)
DK (5) DK2296684T3 (es)
ES (5) ES2531963T3 (es)
HK (6) HK1150305A1 (es)
HR (1) HRP20150116T1 (es)
HU (1) HUE026798T2 (es)
PL (5) PL2491942T3 (es)
PT (4) PT2491942E (es)
SI (1) SI2650008T1 (es)
WO (2) WO2009143865A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
MX2011004306A (es) 2008-10-22 2011-07-28 Genentech Inc Modulacion de degeneracion de axones.
WO2010065850A2 (en) * 2008-12-04 2010-06-10 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) * 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
PL2902035T3 (pl) * 2010-10-14 2019-04-30 Xigen Inflammation Ltd Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
CA2807036C (en) * 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CN101974083A (zh) * 2010-10-20 2011-02-16 中国医学科学院医学生物学研究所 抗hsv1病毒感染的人源hirrp蛋白分子
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197193A2 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206563A2 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2016055160A2 (en) * 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN103911462B (zh) * 2014-04-03 2015-06-10 河北国际旅行卫生保健中心 黄热、乙型脑炎、基孔肯雅、西尼罗的鉴别检测方法及引物和探针
WO2015150934A1 (en) * 2014-04-04 2015-10-08 Feligioni Marco Cell-permeable peptide system for treating diseases caused by glutamate excitotoxicity
CN113509541A (zh) * 2014-06-26 2021-10-19 埃克西金炎症有限公司 Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
EP3313428A1 (en) * 2015-06-26 2018-05-02 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
JP6949057B2 (ja) * 2016-06-02 2021-10-13 セルジーン コーポレイション 動物及びヒトの抗トリパノソーマならびに抗リーシュマニア薬
WO2019152808A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
CN116003530B (zh) * 2022-12-27 2023-12-15 西湖大学 一种针对白细胞介素-6的d-蛋白抑制剂及其应用

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (it) 1981-12-22 1988-10-12 Anic Spa Metodo per la preparazione di gem-diammino derivati n-monoacilati
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IT1190389B (it) 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (it) 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992018138A1 (en) 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
WO1994004562A1 (en) 1992-08-13 1994-03-03 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
BR9306984A (pt) 1992-08-27 1999-01-12 Deakin Res Ltd Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
US5545551A (en) 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
AU6568594A (en) 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
WO1995014772A1 (fr) 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
WO1996034093A1 (en) 1995-04-25 1996-10-31 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
AU7366896A (en) 1995-09-21 1997-04-09 Innapharma, Inc. Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6187817B1 (en) 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998023781A1 (en) 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
WO1998047913A2 (en) 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
AU755154B2 (en) 1997-05-15 2002-12-05 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US20040152084A1 (en) 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
US6306993B1 (en) 1997-05-21 2001-10-23 The Board Of Trustees Of The Leland Stanford, Jr. University Method and composition for enhancing transport across biological membranes
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
EP0897002A3 (en) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6420031B1 (en) 1997-11-03 2002-07-16 The Trustees Of Princeton University Highly transparent non-metallic cathodes
EP1025102B1 (en) 1997-10-20 2004-05-19 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
US6270956B1 (en) 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CA2330458A1 (en) 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
EP1076711A2 (en) 1998-05-13 2001-02-21 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO1999058561A1 (fr) 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
WO1999066061A1 (fr) 1998-06-18 1999-12-23 Dnavec Research, Inc. Phage de transfert d'acide nucleique
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
CN1330675A (zh) 1998-08-28 2002-01-09 格莱风科学公司 精确长度的聚酰胺链、其制备方法和其与蛋白质的缀合物
JP2002525329A (ja) 1998-09-25 2002-08-13 セフアロン・インコーポレーテツド 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する／処置するための方法
US6656474B1 (en) 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
AU765983B2 (en) 1999-05-28 2003-10-09 Apoptosis Technology, Inc. Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
AU5316900A (en) * 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2000075164A1 (en) 1999-06-07 2000-12-14 Mirus Corporation COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AU769315B2 (en) 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
EP1210362A2 (en) 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
IL149933A0 (en) 1999-12-06 2002-11-10 Gen Hospital Corp Pancreatic stem cells and their use in transplantation
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
CA2425610A1 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
DK1333846T3 (da) 2000-10-17 2012-08-06 Diatranz Otsuka Ltd Fremstilling og xenotransplantation af porcine øer
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical INHIBITOR OF JNK
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
JP4234999B2 (ja) 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成
WO2003008553A2 (en) 2001-07-17 2003-01-30 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EP1487870A2 (en) 2002-01-09 2004-12-22 Université de Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2478338A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
BR0314603A (pt) 2002-09-20 2005-07-26 Alcon Inc Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
ATE350480T1 (de) 2002-10-11 2007-01-15 Imvision Gmbh Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen
US20040186052A1 (en) 2002-10-24 2004-09-23 Suhasini Iyer Cytomodulating peptides and methods for treating neurological disorders
EP1578365A4 (en) 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
MXPA05005161A (es) 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
EP1599475A2 (en) * 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
US20080090770A1 (en) 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
DK2351844T3 (da) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
US20060222657A1 (en) 2003-06-20 2006-10-05 Dowdy Steven F Polypeptide transduction and fusogenic peptides
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
KR20060134198A (ko) * 2004-04-08 2006-12-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｊｎｋ 저해제 및 시클로스포린을 포함하는 조성물
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1656951A1 (en) 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US20070015779A1 (en) 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2006130297A2 (en) * 2005-04-29 2006-12-07 Celgene Corporation Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
US20070003531A1 (en) * 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
AU2006311910A1 (en) * 2005-11-03 2007-05-18 Irm Llc Protein kinase inhibitors
EP2049152A2 (en) 2006-06-30 2009-04-22 Kim Laboratories, Inc. Antibodies for norovirus
WO2008006046A1 (en) 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
WO2008094208A2 (en) 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
MX2009002229A (es) * 2006-09-08 2009-03-16 Hoffmann La Roche Benzotriazoles como moduladores de cinasas.
GB0702259D0 (en) 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
PL2285364T3 (pl) 2008-05-07 2015-04-30 Univ California Terapeutyczne uzupełnienie i wzbogacenie smarowania powierzchni oka
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010065850A2 (en) 2008-12-04 2010-06-10 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
AU2010210426B2 (en) 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
CN102365093A (zh) 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
PL2902035T3 (pl) 2010-10-14 2019-04-30 Xigen Inflammation Ltd Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Also Published As

Publication number Publication date
CN102112149A (zh) 2011-06-29
DK2489361T3 (da) 2014-06-30
HK1175102A1 (en) 2013-06-28
HK1221413A1 (zh) 2017-06-02
AU2009253346B2 (en) 2014-07-10
WO2009143865A1 (en) 2009-12-03
DK2296684T3 (da) 2013-03-25
SI2650008T1 (sl) 2015-03-31
DK2650007T3 (en) 2015-07-06
ES2481915T3 (es) 2014-07-31
HK1186988A1 (en) 2014-03-28
CY1115357T1 (el) 2017-01-04
EP2296684A1 (en) 2011-03-23
PT2650008E (pt) 2015-03-02
EP2985031A1 (en) 2016-02-17
HK1186989A1 (en) 2014-03-28
ES2400988T3 (es) 2013-04-16
PL2489361T3 (pl) 2014-08-29
EP2489361B1 (en) 2014-04-16
JP2011524861A (ja) 2011-09-08
PT2491942E (pt) 2013-12-23
PL2650007T3 (pl) 2015-12-31
CA2725545A1 (en) 2009-12-03
HK1150305A1 (en) 2011-11-25
JP5824085B2 (ja) 2015-11-25
ES2531963T3 (es) 2015-03-23
US20110183888A1 (en) 2011-07-28
PT2650007E (pt) 2015-08-04
HUE026798T2 (en) 2016-07-28
EP2650007A1 (en) 2013-10-16
HRP20150116T1 (en) 2015-03-27
PT2489361E (pt) 2014-05-29
CN104147591A (zh) 2014-11-19
CN104147591B (zh) 2017-04-12
JP2014111646A (ja) 2014-06-19
HK1174839A1 (en) 2013-06-21
EP2489361A1 (en) 2012-08-22
EP2650008B1 (en) 2014-12-17
PL2650008T3 (pl) 2015-05-29
CY1116175T1 (el) 2017-02-08
EP2491942B1 (en) 2013-10-23
JP5485265B2 (ja) 2014-05-07
US9006185B2 (en) 2015-04-14
US9610330B2 (en) 2017-04-04
DK2491942T3 (da) 2014-01-13
EP2650007B1 (en) 2015-05-20
AR070864A1 (es) 2010-05-12
CY1116633T1 (el) 2017-03-15
JP2015232008A (ja) 2015-12-24
PL2296684T3 (pl) 2013-05-31
EP2296684B1 (en) 2012-12-05
PL2491942T3 (pl) 2014-03-31
EP2985031B1 (en) 2017-04-12
EP2650008A1 (en) 2013-10-16
CY1114725T1 (el) 2016-10-05
ES2443347T3 (es) 2014-02-19
AU2009253346A1 (en) 2009-12-03
US20150246099A1 (en) 2015-09-03
WO2009144037A1 (en) 2009-12-03
EP2491942A1 (en) 2012-08-29
DK2650008T3 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
ES2544640T3 (es) Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales JNK para el tratamiento de diversas enfermedades autoinmunes
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
EA201070422A1 (ru) Производные оксадиазола
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
WO2007110868A3 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EA201791281A1 (ru) Соединения-коагонисты гип и гпп-1
MX2009006227A (es) Inhibidores de aspartil proteasa que contienen un sistema de anillo triciclico.
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
MA34077B1 (fr) Nouveau peptides et procedes pour leur preparation, ain que leur utilisation
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
DK1727551T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet
IL183165A (en) Polypeptides derived from the extracellular protein of the trem-1 protein and which can be used as antagonists of the trem-1 protein, preparations containing them and their uses for the preparation of a drug for the treatment of sepsis, septic shock and sepsis-like conditions
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
EA200702208A1 (ru) Ингибиторы дипептидилпептидазы-iv
DK1727550T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepin-derivat og en inhibitor for RVS-fusions-proteinet
ZA200704154B (en) Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.